SUBSTANCE AGNOSTIC. MULTIPLE THERAPEUTIC AREAS.
The Alveon SDV platform is designed to deliver a broad range of plant-based and phytopharmaceutical active ingredients through a certified medical device. Medical cannabis is the first validated application. Further therapeutic areas are being actively explored.
PLATFORM LOGIC
One platform. Multiple applications.
The core architecture of the Alveon SDV platform — its patented ceramic dosing mechanism, metered-dose delivery system, and substance-agnostic aerosol generator — can be adapted to a wide range of phytopharmaceutical formulations.
This flexibility enables Alveon and its partners to address multiple therapeutic areas within a single, certified device ecosystem.
Application Example: Medical cannabis.
PROJECT PARTNERS
Precisely dosed medical cannabis therapy for the European market
A SUCCESSFUL JOINT VENTURE
​
Medical cannabis is Alveon's first fully developed therapeutic application. Through Alvify GmbH, a joint venture with Canify AG, the Alveon SDV platform is being commercialised as a metered-dose inhalation device for pharmaceutical-grade cannabis extracts, targeting pharmacy distribution across the European market.
​
The Alvify 1 addresses a structural gap in medical cannabis therapy: the absence of a certified, precisely dosed inhalation device that meets the standards required for prescription use and healthcare reimbursement.
​
BENEFITS OF MEDICAL CANNABIS INHALATION
​
Inhalation provides a significantly faster onset of action compared to oral administration, while metered-dose delivery ensures reproducible pharmacokinetic profiles — a prerequisite for evidence-based therapeutic protocols and clinical trial design.
The Alveon SDV platform delivers these properties through a device certified to pharmaceutical standards, distinguishing it fundamentally from consumer vaporisers and unregulated inhalation products.
POTENTIAL
Further therapeutic
areas.
The Alveon SDV platform is engineered for application beyond medical cannabis.
Phytopharmaceuticals, botanical extracts, and bio-based active ingredients with suitable thermal vaporisation profiles represent natural extensions of the platform technology.
Alveon is actively seeking development and licensing partners for additional therapeutic applications.